1. Skip to Menu
  2. Skip to Content
  3. Skip to Footer

Books

Available from ClinLab Navigator: Essentials of Transfusion Medicine, a convenient and comp...

Books
  • Books

    Books

  • Brand NEW APP - Lab Test Navigator: 800+ Lab Tests for iPhone

    Brand NEW APP - Lab Test Navigator: 800+ Lab Tests for iPhone

  • Brand NEW App - Lab Test Navigator: 800+ Lab Tests for iPad

    Brand NEW App - Lab Test Navigator: 800+ Lab Tests for iPad

Previous
Next

Ganciclovir

Ganciclovir is an analog of acyclovir and is the first antiviral agent approved for the treatment of cytomegalovirus (CMV) infection. It is widely used for the treatment of CMV infections among patients with impaired cell-mediated immunity such as HIV/AIDS and recipients of solid organ and bone marrow transplantation who are at high risk for invasive CMV disease.

Valcyte (valganciclovir) is an oral prodrug of ganciclovir ester that is converted to ganciclovir in the bloodstream. The oral dose is designed to deliver ganciclovir equivalent to intravenous ganciclovir at 5 mg/kg.

Ganciclovir is converted to ganciclovir triphosphate, which is a competitive inhibitor of deoxyguanosine triphosphate. Incorporation of ganciclovir triphosphate into DNA inhibits viral DNA polymerases more than cellular DNA polymerases and disrupts viral DNA synthesis. The circulating half-life is two to four hours. Ganciclovir is excreted unmodified in the urine.

Both ganciclovir and valganciclovir are associated with bone marrow suppression, especially leukopenia. Monitoring of ganciclovir serum concentrations is most useful in guiding therapy of patients with renal dysfunction. Serum creatinine and complete blood count should be checked at least weekly during induction therapy and at least monthly during maintenance therapy.

Therapeutic ranges have not been well-established for ganciclovir. They are based on typical values seen during ganciclovir therapy and do not correlate well to toxicity or outcome.

Reference Values using HPLC for quantitation are:

Trough: 1.0-3.0 ug/mL

Peak: 3.0-12.5 ug/mL

Serum for a peak level should be drawn 30 to 60 minutes after dosing. Serum for a trough level should be drawn no more than 30 minutes before the next dose.

Specimen requirement is a plain red top tube of blood without gel.

Updated Articles

Linearity

The approximate linear range of each analyte is generally specified by the manufacturer or in the literature, but should be confirmed by each laboratory. If a linear relationship between analyte concentration and method response is not obtained, it…

New Articles

Heparin…

Heparin contamination of specimens is a common cause of an unexpected activated plasma thromboplastin time (aPTT) prolongation. In one study, heparin contamination accounted for 39% of unexpected aPTT prolongations in patients who were not receiving…

Blog

Serologic Screening…

Genital herpes is a prevalent sexually transmitted infection (STI) in the United States. Centers for Disease Control and Prevention (CDC) estimates that almost 1 in 6 persons aged 14 to 49 years have genital herpes. Genital herpes infection is…

Stay Informed

Amazon Book

Our Sponsors

Login Form

Lectures

Cases That Kept Me Up At Night: Case #1

Case #1 is an overview of transfusion reactions and a discussion of a neonate with both NAIT and Rh HDN.

View More Lectures

Mobile Applications

iPad mini Horz Vert 300w

Get it for: iPhoneiPad

ClinLab Navigator Information

McAfee SECURE sites help keep you safe from identity theft, credit card fraud, spyware, spam, viruses and online scams
© 2015 ClinLab Navigator, LLC.